Edwards Lifesciences Corp — Form 8-K
Filed November 19, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Edwards Lifesciences amended and restated its Five Year Credit Agreement dated November 19, 2026 with Bank of America as Administrative Agent and multiple lender syndicates. The facility maintains $750M in aggregate commitments ($525M Multicurrency, $125M Yen-enabled, $100M Singapore Dollar-enabled) with maturity extended to November 19, 2031. The restatement replaces the prior July 15, 2022 agreement and updates interest rate mechanics, borrower structure, and covenant terms.
Why this rating
Routine credit facility refinancing/amendment. $750M commitment is <2% of company's $45.9B market cap. Standard terms, no material changes disclosed.
See more from November 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.